Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Total Liabilities (2020 - 2025)

Mirum Pharmaceuticals has reported Total Liabilities over the past 6 years, most recently at $528.1 million for Q4 2025.

  • Quarterly results put Total Liabilities at $528.1 million for Q4 2025, up 18.65% from a year ago — trailing twelve months through Dec 2025 was $528.1 million (up 18.65% YoY), and the annual figure for FY2025 was $528.1 million, up 18.65%.
  • Total Liabilities for Q4 2025 was $528.1 million at Mirum Pharmaceuticals, up from $493.1 million in the prior quarter.
  • Over the last five years, Total Liabilities for MIRM hit a ceiling of $528.1 million in Q4 2025 and a floor of $88.4 million in Q1 2021.
  • Median Total Liabilities over the past 5 years was $373.3 million (2023), compared with a mean of $318.6 million.
  • Biggest five-year swings in Total Liabilities: surged 727.26% in 2021 and later rose 9.01% in 2025.
  • Mirum Pharmaceuticals' Total Liabilities stood at $174.4 million in 2021, then increased by 20.88% to $210.9 million in 2022, then soared by 88.72% to $398.0 million in 2023, then rose by 11.85% to $445.1 million in 2024, then increased by 18.65% to $528.1 million in 2025.
  • The last three reported values for Total Liabilities were $528.1 million (Q4 2025), $493.1 million (Q3 2025), and $470.7 million (Q2 2025) per Business Quant data.